Advertisement

Document › Details
Consilium Strategic Communications Ltd.. (10/15/20). "Press Release: Consilium Strategic Communications Advises Compass Pathways on Its Successful Initial Public Offering". London.
Mental health care company raises $146.6 million on Nasdaq
Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised on the successful initial public offering (IPO) of COMPASS Pathways (“COMPASS”) on Nasdaq. The offering raised $146.6 million. COMPASS began trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS”.
COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. It is pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support from specially trained therapists. Its initial focus is on treatment-resistant depression, an area of significant unmet medical need.
The Consilium team was led by Amber Fennell and supported by Chris Gardner, David Daley, Alix Floyd, Olivia Manser, Lizzie Seeley and Maya Bennison. Consilium continues to advise the company on its financial communications as a publicly listed company. Cowen, Evercore ISI and Berenberg acted as Joint Global Coordinators and Joint Bookrunners in the offering.
Proceeds from the IPO will be used to fund clinical trials, therapist training and other activities to support the development of COMPASS’ investigational COMP360 psilocybin therapy; to fund research and clinical development activities to support the progression of the COMP360 psilocybin therapy for other neuropsychiatric indications; to fund general business development activities; and to fund general and administrative expenses, working capital and other general corporate purposes.
Commenting on COMPASS’ successful IPO, Amber Fennell, Partner and Co-Founder of Consilium Strategic Communications, said: “We are delighted to have supported COMPASS through this major milestone. The team at COMPASS have an impressive vision of a world of mental wellbeing which we are proud to help them communicate internationally. We look forward to supporting COMPASS as a listed company as it continues to transform mental health care.”
Consilium also advised on the communications surrounding the Nasdaq listing of Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, in September 2020. Silence Therapeutics is led by recently appointed President and CEO, Mark Rothera, based in US, and has commenced a search for a US based CFO as it strengthens its team and increases its visibility into the US.
-ENDS-
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
[email protected]
www.consilium-comms.com
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.
Record changed: 2024-12-23 |
Advertisement

More documents for ICR (Group)
- [1] Citryll B.V.. (12/9/24). "Press Release: Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders". Oss....
- [2] ICR Inc.. (10/22/24). "Press Release: ICR Healthcare Launches as a Unified Global Brand in Healthcare Strategic Communications and Investor Relations". New York, NY & London....
- [3] ICR Inc.. (9/12/23). "Press Release: ICR Acquires Consilium Strategic Communications, Creating Global Leader in Healthcare Communications and Investor Relations". New York, NY....
- [4] Consilium Strategic Communications Ltd.. (2/20/23). "Press Release: Consilium Strategic Communications Expands International Presence in US and Europe with Two Senior Strategic Advisor Appointments". London....
- [5] Alentis Therapeutics AG. (1/9/23). "Press Release: Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1". Basel....
- [6] Consilium Strategic Communications Ltd.. (5/6/22). "Press Release: Consilium Strategic Communications Appoints Tracy Cheung as Partner". London....
- [7] OMass Therapeutics Ltd.. (4/28/22). "Press Release: OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases". Oxford....
- [8] Glycotope GmbH. (3/24/22). "Press Release: Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform". Berlin....
- [9] Emergex Vaccines Holding Ltd.. (11/18/20). "Press Release: Emergex Vaccines Raises US$11 Million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases". Abingdon....
- [10] Consilium Strategic Communications Ltd.. (11/10/20). "Press Release: Consilium Strategic Communications Strengthens Global Team in the US and Europe". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top